6-pyrimidinyl-pyrimid-4-one derivative

ABSTRACT

A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: 
                         
which is used for preventive and/or therapeutic treatment of a disease caused by abnormal activity of tau protein kinase 1 such as a neurodegenerative diseases (e.g. Alzheimer disease).

RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No.12/677,213, which is a National Stage Application of InternationalApplication No. PCT/JP2008/066936, filed Sep. 12, 2008, which claimspriority to European Application No. 08290028.3, filed Jan. 11, 2008;and Japanese Application Nos. 2007-275713, filed Sep. 25, 2007; and2007-269485, filed Sep. 14, 2007. Application Ser. No. 12/677,213 andPCT/JP2008/066936 are hereby incorporated by reference herein in theirentireties.

TECHNICAL FIELD

The present invention relates to compounds that are useful as an activeingredient of a medicament for preventive and/or therapeutic treatmentof diseases mainly caused by abnormal activity of tau protein kinase 1(TPK1 also called GSK3beta glycogen synthase kinase 3 beta), such asneurodegenerative diseases (e.g. Alzheimer disease).

BACKGROUND ART

Alzheimer disease is progressive senile dementia, in which markedcerebral cortical atrophy is observed due to degeneration of nerve cellsand decrease of nerve cell number. Pathologically, numerous senileplaques and neurofibrillary tangles are observed in brain. The number ofpatients has been increased with the increment of aged population, andthe disease arises a serious social problem. Although various theorieshave been proposed, a cause of the disease has not yet been elucidated.Early resolution of the cause has been desired.

It has been known that the degree of appearance of two characteristicpathological changes of Alzheimer disease well correlates to the degreeof intellectual dysfunction. Therefore, researches have been conductedfrom early 1980's to reveal the cause of the disease through molecularlevel investigations of components of the two pathological changes.Senile plaques accumulate extracellularly, and β amyloid protein hasbeen elucidated as their main component (abbreviated as “Aβ” hereinafterin the specification: Biochem. Biophys. Res. Commun., 120, 885 (1984);EMBO J., 4, 2757 (1985); Proc. Natl. Acad. Sci. USA, 82, 4245 (1985)).In the other pathological change, i.e., the neurofibrillary tangles, adouble-helical filamentous substance called paired helical filament(abbreviated as “PHF” hereinafter in the specification) accumulateintracellularly, and tau protein, which is a kind ofmicrotubule-associated protein specific for brain, has been revealed asits main component (Proc. Natl. Acad. Sci. USA, 85, 4506 (1988); Neuron,1, 827 (1988)).

Furthermore, on the basis of genetic investigations, presenilins 1 and 2were found as causative genes of familial Alzheimer disease (Nature,375, 754 (1995); Science, 269, 973 (1995); Nature. 376, 775 (1995)), andit has been revealed that presence of mutants of presenilins 1 and 2promotes the secretion of Aβ (Neuron, 17, 1005 (1996); Proc. Natl. Acad.Sci. USA, 94, 2025 (1997)). From these results, it is considered that,in Alzheimer disease, Aβ abnormally accumulates and agglomerates due toa certain reason, which engages with the formation of PHF to cause deathof nerve cells. It is also expected that extracellular outflow ofglutamic acid and activation of glutamate receptor responding to theoutflow may possibly be important factors in an early process of thenerve cell death caused by ischemic cerebrovascular accidents.

It has been reported that kainic acid treatment that stimulates the AMPAreceptor, one of glutamate receptor, increases mRNA of the amyloidprecursor protein (abbreviated as “APP” hereinafter in thespecification) as a precursor of Aβ (Society for Neuroscience Abstracts,17, 1445 (1991)), and also promotes metabolism of APP (The Journal ofNeuroscience, 10, 2400 (1990)). Therefore, it has been stronglysuggested that the accumulation of Aβ is involved in cellular death dueto ischemic cerebrovascular disorders. Other diseases in which abnormalaccumulation and agglomeration of Aβ are observed include, for example,Down syndrome, cerebral bleeding due to solitary cerebral amyloidangiopathy, Lewy body disease and the like. Furthermore, as diseasesshowing neurofibrillary tangles due to the PHF accumulation, examplesinclude progressive supranuclear palsy, subacute sclerosingpanencephalitic parkinsonism, postencephalitic parkinsonism, pugilisticencephalitis, Guam parkinsonism-dementia complex, Lewy body disease andthe like.

The tau protein is generally composed of a group of related proteinsthat forms several bands at molecular weights of 48-65 kDa inSDS-polyacrylamide gel electrophoresis, and it promotes the formation ofmicrotubules. It has been verified that tau protein incorporated in thePHF in the brain suffering from Alzheimer disease is abnormallyphosphorylated compared with usual tau protein (J. Biochem., 99, 1807(1986); Proc. Natl. Acad. Sci. USA, 83, 4913 (1986)). An enzymecatalyzing the abnormal phosphorylation has been isolated. The proteinwas named as tau protein kinase 1 (abbreviated as “TPK1” hereinafter inthe specification), and its physicochemical properties have beenelucidated (J. Biol. Chem., 267, 10897 (1992)). Moreover, cDNA of ratTPK1 was cloned from a rat cerebral cortex cDNA library based on apartial amino acid sequence of TPK1, and its nucleotide sequence wasdetermined and an amino acid sequence was deduced. As a result, it hasbeen revealed that the primary structure of the rat TPK1 corresponds tothat of the enzyme known as rat GSK-3β (glycogen synthase kinase 3β,FEBS Lett., 325, 167 (1993)).

It has been reported that Aβ, the main component of senile plaques, isneurotoxic (Science, 250, 279 (1990)). However, various theories havebeen proposed as for the reason why Aβ causes the cell death, and anyauthentic theory has not yet been established. Takashima et al. observedthat the cell death was caused by Aβ treatment of fetal rat hippocampusprimary culture system, and then found that the TPK1 activity wasincreased by Aβ treatment and the cell death by Aβ was inhibited byantisense of TPK1 (Proc. Natl. Acad. Sci. USA, 90, 7789 (1993);EP616032).

In view of the foregoing, compounds which inhibit the TPK1 activity maypossibly suppress the neurotoxicity of Aβ and the formation of PHF andinhibit the nerve cell death in the Alzheimer disease, thereby cease ordefer the progress of the disease. The compounds may also be possiblyused as a medicament for therapeutic treatment of ischemiccerebrovascular disorder, Down syndrome, cerebral amyloid angiopathy,cerebral bleeding due to Lewy body disease and the like by suppressingthe cytotoxicity of Aβ. Furthermore, the compounds may possibly be usedas a medicament for therapeutic treatment of neurodegenerative diseasessuch as progressive supranuclear palsy, subacute sclerosingpanencephalitic parkinsonism, postencephalitic parkinsonism, pugilisticencephalitis, Guam parkinsonism-dementia complex, Lewy body disease,Pick's disease, corticobasal degeneration and frontotemporal dementia,vascular dementia, traumatic injuries, brain and spinal cord trauma,peripheral neuropathies, retinopathies and glaucoma, as well as otherdiseases such as non-insulin dependent diabetes, obesity, manicdepressive illness, schizophrenia, alopecia, breast cancer, non-smallcell lung carcinoma, thyroid cancer, T or B-cell leukemia, and severalvirus-induced tumors.

Inhibitors of human TPK1 may also inhibit pfGSK3, an ortholog of thisenzyme found in Plasmodium falciparum, as a consequence they could beused for the treatment of malaria (Biochimica et Biophysica Acta 1697,181-196, 2004).

Recently, both human genetics and animal studies have pointed out therole of Wnt/LPR5 pathway as a major regulator of bone mass accrual.Inhibition of TPK1 leads to the consequent activation of canonical Wntsignalling. Because deficient Wnt signalling has been implicated indisorders of reduced bone mass, TPK1 inhibitors may also be used fortreating disorders of reduced bone mass, bone-related pathologies,osteoporosis.

According to recent data, TPK1 inhibitors might be used in the treatmentor prevention of Pemphigus vulgaris.

Recent studies show that TPK1 inhibitor treatment improves neutrophiland megakaryocyte recovery. Therefore, TPK1 inhibitors will be usefulfor the treatment of neutropenia induced by cancer chemotherapy.

Some 6-pyrimidinyl-pyrimid-2-one derivatives are already known to beactive as TPK1 inhibitors (WO03/027080), nevertheless, it has beensurprisingly found that the compound of formula (I) present a better invivo activity without inhibition of cytochrome P450 2D6 CYP 2D6. Thiswill contribute significantly to the develop ability of the compound.

Further, it is generally essential that compounds used as a medicine arestudied in view of a combined administration with other drugs. This isincreasing with recent diversification of medical treatment and aging ofsociety. In order to avoid drug-drug interactions it is hoped that, forinstance, one of the compounds administered does not inhibit cytochromeP450 enzymes, such as cytochrome P450 2D6. This could lead tounpredictable side effects related to the drug combination.

From the known compounds of WO03/027080, the in vitro activities werecomparable and therefore it was expected that all these compounds wouldhave a similar profile. Surprisingly, it was found that one of thecompounds generically covered but not exemplified in WO03/027080 wassignificantly different from the other disclosed compounds.

DISCLOSURE OF THE INVENTION

An object of the present invention is to provide a compound useful as anactive ingredient of a medicament for preventive and/or therapeutictreatment of diseases such as Alzheimer disease, with improved in vivoactivity without inhibition of cytochrome 2D6. More specifically, theobject is to provide a novel compound useful as an active ingredient ofa medicament that enables radical prevention and/or treatment of theneurodegenerative diseases such as Alzheimer disease by inhibiting theTPK1 activity to suppress the neurotoxicity of Aβ and the formation ofthe PHF and by inhibiting the death of nerve cells with improved in vivoactivity without inhibition of CYP 2D6.

It was surprisingly found that a novel compound represented by thefollowing formula (I) had the desired activity and were useful as anactive ingredient of a medicament for preventive and/or therapeutictreatment of the aforementioned diseases. The present invention wasachieved on the basis of these findings.

The present invention thus provides a compound represented by theformula (I):

{3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one}or a Pharmaceutically Acceptable Salt Thereof

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt as a medicament.

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt as a tau protein kinase 1inhibitor.

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt as a medicament used forpreventive and/or therapeutic treatment of a disease caused by tauprotein kinase 1 hyperactivity.

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt for preventive and/or therapeutictreatment of a neurodegenerative disease.

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt for preventive and/or therapeutictreatment of Alzheimer disease, ischemic cerebrovascular accidents, Downsyndrome, cerebral bleeding due to cerebral amyloid angiopathy,progressive supranuclear palsy, subacute sclerosing panencephaliticparkinsonism, postencephalitic parkinsonism, pugilistic encephalitis,Guam parkinsonism-dementia complex, Lewy body disease, Pick's disease,corticobasal degeneration, frontotemporal dementia, vascular dementia,traumatic injuries, brain and spinal cord trauma, peripheralneuropathies, retinopathies and glaucoma.

The present invention relates to3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt for preventive and/or therapeutictreatment of a disease selected from the group consisting of non-insulindependent diabetes, obesity, manic depressive illness, schizophrenia,alopecia, breast cancer, non-small cell lung carcinoma, thyroid cancer,T or B-cell leukemia, osteoporosis, malaria, neutropenia induced bycancer chemotherapy and a virus-induced tumor.

Previous studies have shown that GSK3 activity decreases Long TermPotentiation, a electrophysiological correlate of memory consolidation,suggesting that inhibitor of this enzyme may have procognitive activity.Procognitive effects of the compound could find application for thetreatment of memory deficits characteristic of Alzheimer's disease,Parkinson disease, age associated memory impairment, mild cognitiveimpairment, brain trauma, schizophrenia and other conditions in whichsuch deficits are observed.

The present invention relates to the formula (I)3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneor a pharmaceutically acceptable salt for therapeutic treatment of adisease characterized by cognitive and memory deficits characteristic ofAlzheimer's disease, Parkinson's disease, age-associated memoryimpairment, mild cognitive impairment, brain trauma, schizophrenia andother conditions in which such deficits are observed.

MODE FOR CARRYING OUT THE INVENTION

Unless otherwise indicated, the following definitions are set forth toillustrate and defined the meaning and scope of the various terms usedto describe the invention herein.

The pharmaceutically acceptable salt of the compound represented by theaforementioned formula (I) may include the salt with inorganic acid suchas hydrochloric acid, hydrobromic acid and the like and the salt withorganic acid such as acetic acid, propionic acid, tartaric acid, fumaricacid, maleic acid, malic acid, oxalic acid, succinic acid, citric acid,benzoic acid and the like.

In addition to the compound represented by the aforementioned formula(I), a pharmaceutically acceptable salt thereof, their solvates andhydrates also fall within the scope of the present invention.

The compounds of the present invention have inhibitory activity in vivoagainst TPK1. Therefore, they can inhibit TPK1 activity in patients ofneurodegenerative diseases such as Alzheimer disease, thereby suppressthe neurotoxicity of Aβ and the formation of PHF and inhibit the nervecell death. Accordingly, the compounds of the present invention areuseful as an active ingredient of a medicament which radically enablespreventive and/or therapeutic treatment of Alzheimer disease. Inaddition, the compounds of the present invention are also useful as anactive ingredient of a medicament for preventive and/or therapeutictreatment of ischemic cerebrovascular accidents, Down syndrome, cerebralbleeding due to solitary cerebral amyloid angiopathy, progressivesupranuclear palsy, subacute sclerosing panencephalitis,postencephalitic parkinsonism, pugilistic encephalosis, Guamparkinsonism-dementia complex, Lewy body disease, Pick's disease,corticobasal degeneration frontotemporal dementia, vascular dementia,traumatic injuries, brain and spinal cord trauma, peripheralneuropathies, retinopathies and glaucoma, non-insulin dependentdiabetes, obesity, manic depressive illness, schizophrenia, alopecia,breast cancer, non-small cell lung carcinoma, thyroid cancer, T orB-cell leukemia, and several virus-induced tumors, osteoporosis,malaria, neutropenia induced by cancer chemotherapy, and a diseasecharacterized by cognitive and memory deficits characteristic ofAlzheimer's disease, Parkinson's disease, age-associated memoryimpairment, mild cognitive impairment, brain trauma, schizophrenia andother conditions in which such deficits are observed.

The compound of the present invention also has low inhibitory activityon CYP2D6, causing less effect on the metabolism of the medicament to beused in combination. Therefore, the side effect is hardly produced frommedicament-medicament interactions even when the medicament is used incombination with other medicaments.

Further, the compound of the present invention presents no significanttoxicities and thus is suitable to be used in a medicament.

As the active ingredient of the medicament of the present invention, asubstance may be used which represented by the aforementioned formula(I) and pharmacologically acceptable salts thereof, and solvates thereofand hydrates thereof. The substance, per se, may be administered as themedicament of the present invention, however, it is desirable toadminister the medicament in a form of a pharmaceutical compositionwhich comprises the aforementioned substance as an active ingredient andone or more of pharmaceutical additives. As the active ingredient of themedicament of the present invention, two or more of the aforementionedsubstance may be used in combination.

A type of the pharmaceutical composition is not particularly limited,and the composition may be provided as any formulation for oral orparenteral administration. For example, the pharmaceutical compositionmay be formulated, for example, in the form of pharmaceuticalcompositions for oral administration such as granules, fine granules,powders, hard capsules, soft capsules, syrups, emulsions, suspensions,solutions and the like, or in the form of pharmaceutical compositionsfor parenteral administrations such as injections for intravenous,intramuscular, or subcutaneous administration, drip infusions,transdermal preparations, transmucosal preparations, nasal drops,inhalants, suppositories and the like.

Dose and frequency of administration of the medicament of the presentinvention are not particularly limited, and they may be appropriatelychosen depending on conditions such as a purpose of preventive and/ortherapeutic treatment, a type of a disease, the body weight or age of apatient, severity of a disease and the like. Generally, a daily dose fororal administration to an adult may be 0.01 to 1,000 mg (the weight ofan active ingredient), and the dose may be administered once a day orseveral times a day as divided portions, or once in several days. Whenthe medicament is used as an injection, administrations may preferablybe performed continuously or intermittently in a daily dose of 0.001 to3000 mg (the weight of an active ingredient) to an adult.

EXAMPLES

The present invention will be explained more specifically with referenceto examples. However, the scope of the present invention is not limitedto the following examples.

Preparation of the Compound of the Present Invention Example 13-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one

The compound of the present invention is prepared by the condensationwith 2-chloro-1-methyl-1H-[4,4]bipyrimidinyl-6-one (intermediate 1) andcorresponding amines (intermediate 19) with the existence of base.

General synthetic scheme of the compound of the present invention is asfollows.

Step 1-1: Ethyl Orotate (Intermediate 3)

Orotic acid monohydrate (intermediate 2, 53.19 g, 0.306 mmol) was addedto a solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (46.51 g, 0.306mmol) in dimethylformamide (85 ml). After the solution was stirred for 5minutes, ethyl iodide (57.14 g, 0.366 mmol) was added to the solutionand the mixture was heated at 60° C. for 5 hours. Water (1000 ml) wasadded to the mixture, and the resulting precipitate was collected byfiltration, washed with water, and dried to give ethyl orotate(intermediate 3, 49.25 g, 88%).

¹H NMR (DMSO-d₆) δ: 1.29 (3H, dt, J=1.5, 6.9 Hz), 4.31 (2H, dq, J=1.2,7.2 Hz), 6.04 (1H, d, J=1.2 Hz), 11.11 (1H, s), 11.37 (1H, s)

MS: [M+H]⁺=185

Melting point: 205.5° C.

Step 1-2: Ethyl 2,6-dichloropyrimidine-4-carboxylate (Intermediate 4)

N,N-Diethylaniline (60 ml, 0.377 mmol) was added to a mixture of ethylorotate (intermediate 3, 97.70 g, 0.531 mmol) and phosphorus oxychloride(120 ml, 1.31 mol) and the mixture was refluxed for 70 minutes. Thesolution was poured into ice water, and the resulting solid wascollected by filtration and washed with water. This solid was dissolvedin ethyl acetate, and the solution was filtered through silica gel. Thefiltrate was dried over sodium sulfate, and concentrated under reducedpressure. The obtained residue was purified by short silica gel columnchromatography (eluent; hexane/ethyl acetate=2/1) to give ethyl2,6-dichloropyrimidine-4-carboxylate (intermediate 4, 99.94 g, 85%).

¹H NMR (CDCl₃) δ: 1.45 (3H, t, J=7.3 Hz), 4.51 (3H, q, J=7.1 Hz), 7.97(1H, s)

MS: [M+H]⁺=221

Melting point: 31.6° C.

Step 1-3: Ethyl pyrimidine-4-carboxylate (Intermediate 5)

Triethylamine (48.03 g, 0.475 mmol) was added to a solution of ethyl2,6-dichloropyrimidine-4-carboxylate (intermediate 4, 38.60 g, 0.175mmol) in tetrahydrofuran (700 ml). The solution was added withPalladium-carbon (5%), and stirred under a hydrogen atmosphere for 6hours. The solid in the reaction system was removed by filtration, andthe filtrate was concentrated under reduced pressure. The obtainedresidue was purified by silica gel column chromatography to give ethylpyrimidine-4-carboxylate (intermediate 5, 23.06 g, 87%).

¹H NMR (CDCl₃) δ: 1.46 (3H, t, J=7.1 Hz), 4.52 (2H, q, J=7.1 Hz), 8.03(1H, dd, J=1.7, 5.0 Hz), 9.00 (1H, d, J=5.0 Hz), 9.42 (1H, d, J=1.4 Hz)

MS: [M+H]⁺=153

Melting point: 36.8° C.

Step 1-4: Ethyl 3-oxo-3-(pyrimidin-4-yl)propionate (Intermediate 6)

A solution of ethanol (16.18 g, 0.351 mol) in diethyl ether (15 ml) wasadded to a solution of sodium hydride (13.71 g, 0.343 mol, 60% inparaffin, paraffin was removed by washing with hexane) in diethyl ether(100 ml). After stirring the mixture for 30 minutes, the solvent wasevaporated under reduced pressure, and toluene (100 ml) was added to theresidue. The solution was added with a solution of ethylpyrimidine-4-carboxylate (intermediate 5, 30.86 g, 0.203 mol) and ethylacetate (30.48 g, 0.346 mol) in toluene (100 ml), and the mixture washeated at 80° C. for 3 hours. The mixture was added with hydrochloricacid and then sodium bicarbonate to be adjusted to pH 4. The solutionwas partitioned between water and ethyl acetate. The organic layer waswashed with brine and dried over sodium sulfate. The solvent wasevaporated under reduced pressure to give ethyl 3-oxo-3-(pyrimidin-4-yl)propionate (intermediate 6, 36.10 g, 92%).

¹H NMR (CDCl₃) δ: 1.35 (3H, t, J=6.9 Hz), 4.31 (2H, q, J=7.2 Hz), 6.47(1H, s), 7.84 (1H, dd, J=1.5, 5.4 Hz), 8.89 (1H, d, J=5.1 Hz), 9.24 (1H,d, J=1.2 Hz), 12.22 (1H, s)

MS: [M+H]⁺=195

Melting point: 52.3° C.

Step 1.5: 2-Mercapto-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (Intermediate7)

A solution of ethyl 3-oxo-3-(pyrimidin-4-yl)propionate (intermediate 6,36.10 g, 0.186 mol), N-methylthiourea (25.40 g, 0.282 mol) and1,8-diazabicyclo[5.4.0]undec-7-ene (29.11 g, 0.191 mol) in ethanol (150ml) was refluxed for 21 hours. A half amount of ethanol was evaporatedunder reduced pressure and hydrochloric acid was added. The resultingprecipitate was collected by filtration, washed with water and dried.The precipitate was stirred in hot ethyl acetate (1000 ml), and theprecipitate was collected by filtration and dried to give2-mercapto-1-methyl-1,1-[4,4′]bipyriraidinyl-6-one (intermediate 7,33.91 g, 83%).

¹H NMR (CDCl₃) δ: 3.59 (3H, s), 6.91 (1H, s), 8.27 (1H, d, J=2.4 Hz),9.08 (1H, d, J=2.1 Hz), 9.41 (1H, s), 11.99 (1H, s)

MS: [M+H]⁺=221

Melting point: 228.0° C. (decomp.)

Step 1-6: 2-Chloro-1-methyl-1H-[4,4′]bipyrimidinyl-6-one (Intermediate1)

A suspension of 2-mercapto-1-methyl-1H-[4,4]bipyrimidinyl-6-one(intermediate 7, 8.8 g, 40 mmol) in a mixed solvent of dimethylformamide(30 ml) and 1,2-dichloroethane (30 ml) was added to phosphorusoxychloride (11.2 ml, 120 mmol), and the mixture was stirred at 65° C.for 50 minutes. The solution was poured into ice-cooled dichloromethane(300 ml), water was added to the solution, and the mixture wasvigorously stirred for 5 minutes. Aqueous sodium carbonate solution(25.4 g, 240 mmol, in water (100 ml)) was added and the pH was adjustedto 8 with saturated aqueous sodium hydrogen carbonate solution. Aqueoussodium hypochlorite solution (5% in water, 120 ml) was added. Afterfiltration with celite, the organic layer was extracted twice withdichloromethane, and washed with saturated aqueous sodium bicarbonatesolution and dried over sodium sulfate. The solvent was evaporated underreduced pressure, and the obtained residue was purified by silica gelcolumn chromatography (eluent; ethyl acetate/hexane=1/1) and washed withdiethyl ether to give 2-chloro-1-methyl-1H-1-[4,4′]bipyrimidinyl-6-one(intermediate 1) as a pale-yellow solid (2.2 g, 62%, purity 98.7%).

¹H NMR (CDCl₃) δ: 3.74 (3H, s), 7.58 (1H, s), 8.19 (1H, d, J=5.7 Hz),8.92 (1H, d, J=5.2 Hz), 9.31 (1H, d, J=1.1 Hz)

MS: [M+H]⁺=223

Melting point: 168.5° C. (decomp.)

Step 1-7: 2-Bromo-(1S)-1-(4-bromophenyl)ethanol (Intermediate 9)

(S)—CBS (25 ml, (S)-2-methyl-CBS-oxazaborolidine, manufactured byAldrich, 1.0 M solution in toluene) was cooled to 0° C., andborane-tetrahydrofuran complex (185 ml, 185 mmol, 1.0 M solution intetrahydrofuran) was added. After the flask was cooled by ice-sodiumchloride bath, a solution of 4-bromophenacyl bromide (intermediate 8,50. 28 g, 181 mmol) in dichloromethane (300 ml) was added dropwise overone hour while maintaining the temperature at −5° C. to 0° C. Afterstirring the mixture at 0° C. for 50 minutes, methanol (12 ml) was addedby small portions. Then, 0.5 M hydrochloric acid (300 ml) was addeddropwise and the mixture was stirred at room temperature for 40 minutes.The precipitate was filtered off and the filtrate was partitionedbetween dichloromethane and water. The organic layer was separated andthe aqueous layer was extracted with methylene chloride. The organiclayers were combined, washed twice with 0.5 M hydrochloric acid andbrine, and dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure to afford2-bromo-1-(1S)-(4-bromophenyl)ethanol (intermediate 9) as a pale-brownoil. This crude product was used for next step without purification.

Step 1-8: (2S)-2-(4-Bromophenyl)oxirane (Intermediate 10)

(2S)-2-Bromo-F(4-bromophenyl)ethanol (intermediate 9) obtained above wasdissolved in ethyl ether (300 ml), the solution was stirred with aqueoussodium hydroxide (14.47 g, 362 mmol in 300 ml of water) in a two-layersystem at room temperature for 1.5 hours. The mixture was partitionedbetween diethyl ether and water, and the organic layer was washed withsaturated brine and dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure to give (2S)-2-(4-bromophenyl)oxirane(intermediate 10) as a pale-brown oil. This crude product was used fornext step without purification.

¹H-NMR (300 MHz, CDCl₃) δ: 2.74-2.77 (1H, m), 3.13-3.17 (1H, m),3.82-3.84 (1H, m), 7.16 (2H, d, J=8.4 Hz), 7.48 (2H, d, J=8.4 Hz)

Step 1-9: (1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino)ethanol(Intermediate 11)

A mixture of (2S)-2-(4-bromophenyl)oxirane (intermediate 10) obtainedabove and (R)-1-phenylethylamine (65.22 g, 538 mmol) was stirred in anoil bath with heating at 80° C. for 3 hours. Excess amine was distilledoff under reduced pressure (ca. 70° C. at 7 mmHg). After cooling,resulting solid residue was washed with isopropyl ether and dried togive (1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino) ethanol(intermediate 11, 46.76 g, 81% yield for 3 steps) as white crystals.

¹H NMR (300 MHz, CDCl₃) δ: 1.39 (3H, d, J=6.3 Hz), 2.48 (1H, dd, J=9.0Hz, 12.0 Hz), 2.77 (1H, dd, J=3.6 Hz, 12.3 Hz), 3.82 (1H, dd, J=6.6 Hz,13.2 Hz), 7.16 (2H, d, J=8.4 Hz), 7.20-7.27 (3H, m), 7.31-7.34 (2H, m),7.41 (2H, d, J=8.4 Hz)

MS: [M+H]⁺=320

Melting point: 106.3° C.

Specific optical rotation; [α]_(D)=+80.74 (c=1.0, dichloromethane)

Step 1-10: (6S)-6-(4-Bromophenyl)-4-((1R)-1-phenylethyl)morpholin-3-one(Intermediate 12)

A solution of chloroacetyl chloride (19.5 ml, 245 mmol) indichloromethane (100 ml) was added dropwise to a ice-cooled solution of(1S)-1-(4-bromophenyl)-2-((1R)-1-phenylethylamino)ethanol (intermediate11, 71.0 g, 222 mmol) and triethylamine (34 ml, 245 mmol) indichloromethane (600 ml). After the mixture was stirred for 2 hours, 1 Mhydrochloric acid was added and the mixture was partitioned betweenwater and chloroform. The organic layer was washed with saturatedaqueous sodium hydrogen carbonate and brine, and dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure andthe residue was dissolved in 2-propanol (600 ml). The solution was addedwith potassium hydroxide (85%, 18.3 g, 278 mmol). The mixture wasstirred at room temperature for 15 hours. The solvent was evaporatedunder reduced pressure and the residue was added with ethyl acetate. Themixture was partitioned between water and ethyl acetate, and the organiclayer was washed with 1 M hydrochloric acid, saturated aqueous sodiumhydrogen carbonate and brine, and dried over anhydrous magnesiumsulfate. The solvent was evaporated under reduced pressure to give(6S)-6-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholin-3-one(intermediate 12, 92 g) as a brown oil. This crude product was used fornext reaction without purification.

¹H-NMR (300 MHz, CDCl₃) δ: 1.53 (3H, d, J=7.0 Hz), 2.96 (1H, dd, J=3.0Hz, 12.2 Hz), 3.29 (1H, dd, J=10.8 Hz, 12.0 Hz), 4.38 (1H, d, J=16.8Hz), 4.49 (1H, d, J=16.9 Hz), 4.53 (1H, dd, J=3.0 Hz, 10.6 Hz), 6.53(1H, q, J=7.2 Hz), 7.14 (2H, d, J=8.3 Hz), 7.28-7.39 (5H, m), 7.45 (2H,d, J=8.4 Hz)

MS: [M+H]⁺=360

Specific optical rotation; [α]_(D)=+71.68 (c=0.5, chloroform)

Step 1-11: (2S)-2-(4-Bromophenyl)-4-((1R)-1-phenylethyl)morpholine(Intermediate 13)

To a ice-cooled solution of(6S)-6-(4-bromophenyl)-4-((1R)-1-phenylethyl) morpholin-3-one(intermediate 12, 92 g) obtained in step 1-10 in tetrahydrofuran (400ml) was added dropwise over 30 minutes a borane-tetrahydrofuran complex(1.0 M solution in tetrahydrofuran, 600 ml, 600 mmol). After beingwarmed to room temperature and stirred for 2 hours, the mixture wasice-cooled again and added dropwise with methanol (70 ml). The solventwas evaporated under reduced pressure. The residue was added withmethanol (750 ml) and 1 M aqueous sodium hydroxide (280 ml). The mixturewas stirred at 80° C. for one hour, during which period 1 M aqueoussodium hydroxide (70 ml) was added 3 times in every 15 minutes. Afterthe mixture was cooled to room temperature, methanol was evaporatedunder reduced pressure and the resulting solution was extracted withethyl acetate. The organic layers was washed with water and brine, anddried over anhydrous sodium sulfate. The solvent was evaporated underreduced pressure to give(25)-2-(4-bromophenyl)-4-((1R)-1-phenylethyl)morpholine (intermediate13, 68 g, yield 88% from intermediate 11) as white crystals.

IR(ATR):1487, 1449, 1117, 1098, 809, 758, 699, 550 cm⁻¹

¹H-NMR (CDCl₃) δ: 1.35 (3H, d), 2.10 (2H, m), 2.60 (1H, m), 3.05 (1H,m), 3.35 (1H, q), 3.75 (1H, m), 3.89 (1H, m), 4.55 (1H, m), 7.25 (7H,m), 7.46 (2H, d)

MS: [M+H]⁺=346

Melting point: 88.0° C.

Specific optical rotation; [α]_(D)=+32.06 (c=1.0, dichloromethane)

Step 1-12: 4-((2S)-4-((1R)-1-Phenylethyl)morpholin-2-yl)benzaldehyde(Intermediate 14)

To a solution of (2S)-2 (4-bromophenyl)-4 ((1R)-1-phenylethyl)morpholine(intermediate 1a, 63.3 g, 183 mmol) in tetrahydrofuran (450 ml) wasadded n-butyllithium (1.57 M in hexane solution, 175 ml, 275 mmol) at−78° C. and the mixture was stirred for 20 minutes.N,N-dimethylformamide (28.3 ml 365 mmol) was added and the mixture wasstirred for 2 hours at −78° C. and then allowed to be warmed to −10° C.The reaction was quenched with aqueous ammonium chloride, and theresulting solution was partitioned between water and ethyl acetate. Theorganic layer was washed with water and brine and dried over sodiumsulfate. The solvent was evaporated under reduced pressure to affordcrude 4-((2S)-4 ((1R)-1-phenylethyl) morpholin-2-yl)benzaldehyde(intermediate 14, 55.1 g). This compound was used without furtherpurification.

Step 1.13: 4-((2S)-4-((1R)-1-Phenylethyl)morpholin-2-yl)benzonitrile(Intermediate 15)

To a solution of crude 4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)benzaldehyde (intermediate 14, 55.1 g) in ethanol (280 ml) was addedsodium acetate (30.0 g, 365 mmol) and hydroxylamine hydrochloride (25.4g, 365 mmol) at room temperature. After a reflux for 2 hours, themixture was partitioned between water and dichloromethane, and theorganic layer was washed with water and brine and dried over sodiumsulfate. The solvent was evaporated under reduced pressure. The residuewas then added with acetic acid (140 ml) and acetic anhydride (140 ml).After the mixture was refluxed for 2 hours, the solvent was removedunder reduced pressure. The residue was partitioned between water andchloroform. The organic layer was washed with aqueous sodium hydrogencarbonate, dried over sodium sulfate, and the solvent was removed underreduced pressure. The residue was purified by silica gel columnchromatography (eluent; hexane/ethyl acetate=9/1) to afford4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)benzonitrile (intermediate15, 45.7 g, 86% from intermediate 13)

¹H NMR (400 MHz, CDCl₃) δ: 1.37 (3H, d, J=7.0 Hz), 2.01 (1H, t, J=11.0Hz), 2.15 (1H, dt, J=3.1, 11.7 Hz), 2.60-2.65 (1H, m), 3.08-3.12 (1H,m), 3.39 (1H, q, J=7.0 Hz), 3.74 (1H, dt, J=2.4, 11.7 Hz), 3.92-3.96(1H, m), 4.65 (1H, dd, J=2.4, 10.2), 7.24-7.35 (5H, m), 7.48 (2H, d,J=7.8 Hz), 7.63 (2H, d, J=7.8 Hz)

MS: [M+H+]⁺=293

Melting point: 83.6° C.

Specific optical rotation; [α]_(D)=+46.23 (c=0.5, chloroform)

Step 1-14: 4-((2S)-Morpholin-2-yl)benzonitrile hydrochloride(Intermediate 16)

To a solution of4-((2S)-4-((1R)-1-phenylethyl)morpholin-2-yl)benzonitrile (intermediate15, 45.7 g, 156 mmol) in 1,2-dichloroethane (312 ml) was added1-chloroethyl chloroformate (66.9 g, 468 mmol) at room temperature.After a reflux for 6 hours, the solution was concentrated under reducedpressure. The residue was dissolved in methanol (312 ml) and thesolution was refluxed for 2 hours. After removal of the solvent underreduced pressure, the crude product was washed with acetone and driedunder reduced pressure to afford 4-((2S)-morpholin-2-yl)benzonitrilehydrochloride (intermediate 16, 27.6 g, 79%).

¹H NMR (400 MHz, DMSO-d₆) δ:2.99 (1H, t, J=11.7 Hz), 3.12 (1H, dt,J=3.1, 12.5 Hz), 3.25-3.28 (1H, m), 3.48-3.52 (1H, m), 3.92 (1H, dt,J=2.4, 11.7 Hz), 4.15 (1H, dd, J=3.1, 12.5 Hz), 4.86 (1H, dd, J=2.4,11.7 Hz), 7.60 (2H, d, J=8.6 Hz), 7.90 (2H, d, J=8.6 Hz), 9.37 (2H, brs)

MS: [M+H]⁺=189

Melting point: 195.8° C.

Specific optical rotation; [α]_(D)=+30.39 (c=0.5, methanol)

Step 1-15: tert-Butyl (2S)-2-(4-cyanophenyl)morpholine-4-carboxylate(Intermediate 17)

To a solution of 4 ((2S)-morpholin-2-yl)benzonitrile hydrochloride(intermediate 16, 17.9 g, 79.8 mmol) in tetrahydrofuran (400 ml) wasadded triethylamine (24.2 g, 240 mmol) and di-tert-butyl dicarbonate(19.2 g, 87.8 mmol) at 0° C. and the mixture was stirred at roomtemperature for 3 hours. The resulting solution was partitioned betweenwater and ethyl acetate, and the organic layer was washed with brine,dried over sodium sulfate, and removed under reduced pressure. Theresidue was purified by silica gel column chromatography (eluent;hexane/ethyl acetate=6/1) to afford tert-butyl(2S)-2-(4-cyanophenyl)morpholine-4-carboxylate (intermediate 17, 17.6 g,77%)

¹H NMR (400 MHz, CDCl₃) δ: 1.49 (9H, s), 2.69-2.80 (1H, m), 3.00-3.09(1H, m), 3.65-3.72 (1H, m), 3.90-4.23 (3H, m), 4.48 (1H, d, J=11.0 Hz),7.50 (2H, d, J=7.8 Hz), 7.66 (2H, d, J=7.8 Hz)

MS: [M+H]⁺=289

Melting point: 104.2° C.

Specific optical rotation; [α]_(D)=−37.35 (c=0.5, chloroform)

Step 1-16: tert-Butyl(2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholine-4-carboxylate(Intermediate 18)

To a solution of tert-butyl(2S)-2-(4-cyanophenyl)morpholine-4-carboxylate (intermediate 17, 17.6 g,61.1 mmol) and hydroxylamine hydrochloride (12.8 g, 183 mmol) in ethanol(120 ml) was added sodium carbonate (32.4 g, 305 mmol) in water (120 ml)at room temperature and the mixture was stirred at 80° C. for 3 hours.After removal of the solvent under reduced pressure, the residue waspartitioned between water and ethyl acetate. The organic layer waswashed with brine and dried over sodium sulfate. The solvent wasevaporated under reduced pressure. The residue was added with xylene(150 ml) and N,N-dimethylacetamide dimethylacetal (18.1 g, 122 mmol).After the solution was refluxed for 2 hours, water was azeotropicallyremoved using a Dean-Stark water separator with molecular sieves 4A. Themixture was concentrated under reduced pressure, and the residue waspurified by silica gel column chromatography (eluent; hexane/ethylacetate=3/1) to afford tert-butyl(2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholine-4-carboxylate(intermediate 18, 16.9 g, 80%)

¹H NMR (400 MHz, CDCl₃) δ: 1.49 (9H, s), 2.66 (3H, s), 2.77-2.90 (1H,m), 3.02-3.11 (1H, m), 3.67-3.74 (1H, m), 3.89-4.25 (3H, m), 4.48 (1H,d, J=11.0 Hz), 7.50 (2H, d, J=7.8 Hz), 8.00 (2H, d, J=7.8 Hz)

MS: [M+H]⁺=246 (-tert-BuOCO)

Melting point: 114.4° C.

Specific optical rotation; [α]_(D)=−34.93 (c=0.5, chloroform)

Step 1-17: (2S)-2-(4-(5-Methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholinehydrochloride (Intermediate 19)

To a solution of tert-butyl(2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholine-4-carboxylate (intermediate 18, 16.9 g, 49.0 mmol) in ethylacetate (60 ml) was added 4N hydrogen chloride in ethyl acetate (150 ml)at room temperature and the solution was stirred for 3 hours. Thesolvent was evaporated under reduced pressure, and the resultingprecipitate was filtered, washed with ethyl acetate, and dried underreduced pressure to afford (2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholine hydrochloride (intermediate 19, 13.3 g, 96%).

¹H NMR (400 MHz, DMSO-d₆) δ: 2.67 (3H, s), 3.00 (1H, t, J=12.5 Hz), 3.12(1H, dt, J=3.9 12.5 Hz), 3.27 (1H, d, J=12.5 Hz), 3.48 (1H, d, J=12.5Hz), 3.97 (1H, dt, J=2.4, 12.5 Hz), 4.15 (1H, dd, J=3.1, 12.5 Hz), 4.89(1H, dd, J=1.6, 11.0 Hz), 7.58 (2H, d, J=8.6 Hz), 8.03 (2H, d, J=8.6Hz), 9.62 (2H, brs)

MS: [M+H]⁺=246

Melting point: 286.8° C.

Specific optical rotation; [α]_(D)=+29.98 (c=0.5, methanol)

Step 1-18:3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one (the Compound of the Present Invention)

To a solution of 2-chloro-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one(9.80 g, 44.0 mmol) and(2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholine hydrochloride(13.3 g, 47.2 mmol) was added triethylamine (13.4 g, 132 mmol) at roomtemperature, and the solution was stirred at room temperature for 4hours. After the solution was concentrated under reduced pressure, theresulting crude product was washed with water, dried under reducedpressure to afford3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3 H)-one (the compound of the present invention, 18.0 g, 89%).

¹H NMR (400 MHz, DMSO-d₆) δ: 2.68 (3H, s), 3.04 (1H, dd, J=11.0, 13.3Hz), 3.21 (1H, dt, J=3.1 12.5 Hz), 3.49 (3H, s), 3.73 (1H, d, J=13.3Hz), 3.80-3.85 (1H, m), 3.94 (1H, dt, J=2.3, 11.7 Hz), 4.11 (1H, dd,J=1.6, 11.7 Hz), 4.86 (1H, dd, J=2.4, 10.2 Hz), 7.02 (1H, s), 7.66 (2H,d, J=7.8 Hz), 8.03 (2H, d, J=7.8 Hz), 8.22 (1H, dd, J=1.6, 5.5 Hz), 9.00(1H, d, J=4.7 Hz), 9.30 (1H, d, J=1.6 Hz)

MS: [M+H]⁺=432

Melting point: 191° C. (de comp.)

Specific optical rotation; [α]_(D)=−53.71 (c=0.5, chloroform)

Chiral HPLC condition;

-   -   Column; DAICEL CHIRALCEL OD-H 250×4.6φmm    -   Eluent; ethanol/n-hexane=80/20    -   Flow rate; 0.5 ml/min    -   Temperature; 40° C.    -   Detection; 242 nm (UV)    -   Retention time; 23.878 min (ref. other isomer; 30.615 min)        Preparation of Comparative Compounds

Example 2 Preparation of Compound 1 of Table 11-Methyl-2-[2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one

Step 2-1: 4-Benzyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)morpholine(Intermediate 21)

To a stirred solution of 4-benzyl-2-morpholinecarboxylic acidhydrochloride (intermediate 20, 1.5 g, 5.82 mmol) inN,N-dimethylformanide (10 ml) was added2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate(2.2 g, 6.98 mmol), 1-hydroxybenzotriazole hydrate (236 mg, 1.74 mmol)and N,N-diisopropylethylamine (5.1 ml, 29.1 mmol), and the reactionmixture was stirred at room temperature for 30 minutes. After theaddition of N′-hydroxybenzamidine (792 mg, 5.82 mmol), the reactionmixture was stirred at room temperature for one hour, and then heated to110° C. When the reaction was complete (checked by thin layerchromatography), excess reagent was decomposed by the addition of waterand the aqueous layer was extracted with ethyl acetate. The extract waswashed with water and brine, dried over magnesium sulfate, andconcentrated in vacuo. The resulting residue was purified by columnchromatography on silica gel, (eluent; 25% ethyl acetate in hexane) toafford 4-benzyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)morpholine(intermediate 21, 1.44 g, 77%) as a colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 2.41-2.47 (1H, m), 2.60 (1H, dd, J=9.8, 11.1Hz), 2.73 (1H, dd, J=1.2, 11.7 Hz), 3.13 (1H, d, J=11.7 Hz), 3.61 (2H,s), 3.85-3.91 (1H, m), 4.11 (1H, dt, J=3.0, 11.5 Hz), 4.99 (1H, dd,J=2.8, 9.4 Hz), 7.26-7.38 (5H, m), 7.45-7.52 (3H, m), 8.09-8.12 (2H, m)

MS: [M+H]⁺=322

Step 2-2: 2-(3-Phenyl-[1,2,4]oxadiazol-5-yl)-morpholine hydrochloride(Intermediate 22)

To a stirred solution of4-benzyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)morpholine (intermediate 21,2.0 g, 6.22 mmol) in 1,2-dichloroethane (10 ml) was added chloroethylchloroformate (2.0 ml, 18.7 mmol), and the reaction mixture was stirredfor at 70° C.4 hours. The reaction mixture was concentrated in vacuo.After removal of the solvent, the residue was dissolved in methanol (10ml), and the reaction solution was stirred for one hour under reflux.When the reaction was complete (checked by thin layer chromatography),the reaction mixture was concentrated in vacuo. The resulting2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-morpholine hydrochloride(intermediate 22) was used for next reaction without furtherpurification.

¹H NMR (400 MHz, DMSO-d₆) δ=3.15-3.22 (1H, m), 3.29-3.32 (1H, m), 3.47(1H, dd, J=10.2, 12.6 Hz), 3.72 (1H, dd, J=2.6, 12.8 Hz), 4.00-4.06 (1H,m), 4.12-4.17 (1H, m), 5.40 (1H, dd, J=2.8, 10.0 Hz), 7.58-7.66 (3H, m),8.03-8.05 (2H, m), 9.65 (2H, br)

MS: [M+H]⁺=232

Melting point: 194.1° C.

Step 2-3;1-Methyl-2-(2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-morpholin-4-yl)-1,1-[4,4′]bipyrimidinyl-6-one;(Compound 1 of Table 1)

A solution of 2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-morpholinehydrochloride (intermediate 22) obtained above in tetrahydrofuran (10ml) was added with 2-chloro-3-methyl-6-(pyrimidine-4-yl)pyrimidin-4-one(intermediate 1, 1.3 g, 6.22 mmol) and triethylamine (4.3 ml, 31.1mmol), and the reaction mixture was stirred at room temperature for 2hours. The solution was partitioned between water and chloroform, andthe organic layer was washed with water and brine, dried over magnesiumsulfate, and concentrated in vacuo. The resulting residue was purifiedby column chromatography on silica gel (eluent; 5% methanol inchloroform) to afford1-methyl-2-(2-(3-phenyl-[1,2,4]oxadiazol-5-yl)-morpholin-4-yl)-1H-[4,4′]bipyrimidinyl-6-one(compound 1 of Table 1, 1.53 g, 59%, 2 steps) as a solid.

¹H NMR (400 MHz, DMSO-ds) δ: 3.47 (3H, s), 3.60-3.70 (3H, m), 3.89-4.11(3H, m), 5.28-5.39 (1H, m), 7.02 (1H, s), 7.56-7.62 (3H, m), 8.00-8.02(2H, m), 8.24 (1H, d, J=4.6 Hz), 9.00 (11-1, d, J=4.6 Hz), 9.29 (1H, s).

MS: 418 (M⁺+1).

Melting point: 166.7° C.

Example 3 Preparation of the Compound 2 in Table 11-Methyl-2-[2-(5-phenyl-[1,2,4]oxadiazol-3-yl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one

Step 3-1: 4-Benzylmorpholine-2-carbonitrile (Intermediate 25)

A mixture of N-benzylethanolamine (intermediate 23, 44.8 ml, 314 mmol)and 2-chloroacrylonitrile (intermediate 24, 25 ml, 314 mmol) was stirredat room temperature for 24 hours. After the mixture was cooled to 0° C.,tetrahydrofuran (300 ml) and then potassium tert-butoxide was added tothe mixture, and the mixture was stirred at 0° C. for one hour. Themixture was diluted by ethyl ether, and then washed with water and brineand dried over magnesium sulfate. Solvent was removed under reducedpressure, and the residue was purified by silica gel columnchromatography (eluent; 5% ethyl acetate in hexane) to afford4-benzylmorpholine-2-carbonitrile (intermediate 25) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 2.41 (1H, ddd, J=3.1, 8.8, 11.8 Hz), 2.56(1H, dd, J=3.2, 11.9 Hz), 2.64 (1H, d, J=11.8 Hz), 2.76 (1H, dd, J=3.8,11.8 Hz), 3.57 (2H, q, J=12.9 Hz), 3.77 (1H, dt, J=3.6, 11.7 Hz), 4.03(1H, ddd, J=2.7, 8.9, 11.7 Hz), 4.60 (1H, t, J=3.6 Hz), 7.26-7.36 (5H,m)

MS: [M+H]⁺=203

Step 3-2: 4-Benzyl-N′-hydroxymorpholine-2-carboxamidine (Intermediate26)

To a stirred solution of 4-benzylmorpholine-2-carbonitrile (intermediate25, 5.0 g, 24.7 mmol) in the mixture of ethanol and water (2/1, 75 ml)was added hydroxylamine hydrochloride (5.2 g, 74.2 mmol) and sodiumbicarbonate (13.1 g, 123.5 mmol), and the reaction mixture was stirredunder reflux for 12 hours. The reaction was diluted with chloroform, andthe reaction mixture was washed with water and brine. The organic layerwas dried over magnesium sulfate, and concentrated in vacuo. Theresulting 4-benzyl-N′-hydroxymorpholine-2-carboxamidine (intermediate26) was used for next reaction without further purification.

Step 3-3: 4-Benzyl-2-(5-phenyl-1,2,4-oxadiazol-3-yl)morpholine(Intermediate 27)

To a stirred solution of benzoic acid (2.30 g, 19.1 mmol) inN,N-dimethylformamide (20 ml) was added2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumtetrafluoroborate(6.15 g, 19.1 mmol), 1-hydroxybenzotriazole hydrate (518 mg, 3.83 mmol)and N,N-diisopropylethylamine (11.0 ml, 63.8 mmol), and the reactionmixture was stirred at room temperature for 30 minutes. After additionof 4-benzyl-N′-hydroxymorpholine-2-carboxamidine (intermediate 26, 3.0g, 12.8 mmol), the reaction mixture was stirred at room temperature forone hour, and then heated to 110° C. When the reaction was complete(checked by thin layer chromatography), excess reagent was decomposed byaddition of water and the aqueous layer was extracted with ethylacetate. The extract was washed with water and brine, dried overmagnesium sulfate, and concentrated in vacuo. The resulting residue waspurified by column chromatography on silica gel (eluent: 30% ethylacetate in hexane) to afford4-benzyl-2-(5-phenyl-1,2,4-oxadiazol-3-yl)morpholine (intermediate 27,3.08 g, 75%) as a colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 2.42 (1H, dt, J=3.3, 11.4 Hz), 2.54 (1H, dd,J=10.7 Hz), 2.76 (1H, dd, J=1.7, 11.5 Hz), 3.13 (1H, dd, J=2.0, 9.6 Hz),3.61 (2H, s), 3.89 (1H, dt, J=2.5, 11.2 Hz), 4.07-4.11 (1H, m), 4.90(1H, dd, J=2.5, 10.2 Hz), 7.26-7.36 (5H, m), 7.50-7.53 (2H, m),7.57-7.61 (1H, m), 8.15-8.16 (2H, m)

MS: [M+H]⁺=322

Step 3-4: 2-(5-Phenyl-[1,2,4]oxadiazol-3-yl)-morpholine hydrochloride(Intermediate 28)

To a stirred solution of4-benzyl-2-(5-phenyl-1,2,4-oxadiazol-3-yl)morpholine (intermediate 27,900 mg, 2.80 mmol) in 1,2-dichloroethane (2.0 ml) was added chloroethylchloroformate (0.46 ml, 4.20 mmol), and the reaction mixture was stirredat 70° C. for 4 hours. The reaction mixture was concentrated in vacuo.After removal of the solvent, the residue was dissolved in methanol (2.0ml), and the solution was stirred under reflux for one hour. When thereaction was complete (checked by thin layer chromatography), thereaction mixture was concentrated in vacuo. The resulting2-(5-phenyl-[1,2,4]oxadiazol-3-yl)-morpholine hydrochloride(intermediate 28) was used for next reaction without furtherpurification.

¹H NMR (400 MHz, DMSO-d₆) δ: 3.17-3.24 (1H, m), 3.30-3.44 (2H, m),3.60-3.64 (1H, m), 3.99 (1H, dt, J=2.3, 12.0 Hz), 4.11-4.15 (1H, m),5.16 (1H, dd. J=2.6, 10.7 Hz), 7.66 (2H, t, J=7.7 Hz), 7.73-7.77 (1H,m), 8.12-8.15 (2H, m), 9.42 (2H, br)

MS: [M+H]⁺=232

Melting point: 111.0° C.

Step 3-5:1-Methyl-2-[2-(5-phenyl-1,2,4]oxadiazol-3-yl)-morpholin-4-yl-1H-[4,4′]bipyrimidinyl-6-one(Compound 2 in Table 1)

A solution of the resulting2-(5-phenyl-[1,2,4]oxadiazol-3-yl)-morpholine hydrochloride(intermediate 28) in tetrahydrofuran (6.0 ml) was added with2-chloro-3-methyl-6-(pyrimidine-4-yl)pyrimidin-4-one (intermediate 1,260 mg, 2.34 mmol) and triethylamine (1.81 ml, 13.0 mmol), and thereaction mixture was stirred at room temperature for 2 hours. Thesolution was partitioned between water and chloroform, and the organiclayer was washed with water and brine, dried over magnesium sulfate, andconcentrated in vacuo. The resulting residue was purified by columnchromatography on silica gel (eluent; 5% methanol in chloroform) toafford1-methyl-2-[2-(5-phenyl-[1,2,4]oxadiazol-3-yl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one(compound 2 in Table 1, 749 mg, 64%, 2 steps) as solid

¹H NMR (400 MHz, DMSO-d₆) δ: 3.47 (3H, s), 3.51-3.68 (3H, m), 3.96-4.10(3H, m), 5.15-5.17 (1H, m), 7.02 (1H, s), 7.67-7.74 (3H, m), 8.13-8.24(3H, m), 9.00 (1H, d, J=4.8 Hz), 9.30 (1H, s).

MS: 418 (M⁺+1).

Melting point: 207.6° C.

Example 4 Preparation of the Compound 3 in Table 12-[2-(4-Furan-3-yl-phenyl)-morpholin-4-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one

Step 4-1: 2-(4-Bromophenyl)oxirane (Intermediate 30)

A mixture of 4-bromobenzaldehyde (intermediate 29, 25.25 g, 136 mmol),trimethylsulfonium iodide (28.71 g, 141 mmol), water (6.5 ml, 361 mmol)and potassium hydroxide (15.56 g, 277 mmol) in acetonitrile (140 ml) waswarmed to 55° C. for 2.5 hours. The resulting solution was partitionedbetween water and diethyl ether, and the organic layer was washed withwater, diluted hydrochloric acid, and brine, and dried over sodiumsulfate. Crude product of 2-(4-bromo-phenyl)-oxirane (intermediate 30)was obtained by removal of organic solvent under reduced pressure, whichwas used for next reaction without purification.

Step 4-2: 2-Benzylamino-1-(4-bromo-phenyl)-ethanol (Intermediate 31)

A mixture of crude product of 2-(4-bromo-phenyl)-oxirane (intermediate30) obtained above and benzylamine (47.00 g, 439 mmol) was heated to 70°C. for 8 hours and the excess benzylamine was distilled off underreduced pressure (ca. 65° C. at 10 mmHg). The residue was cooled to besolidified, which was washed with diisopropyl ether to afford2-benzylamino-1-(4-bromo-phenyl)-ethanol (intermediate 31, 23.63 g, 57%from 4-bromobenzaldehyde) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ:2.68 (1H, dd, J=9.0, 12.2 Hz), 2.92 (1H, dd,J=3.6, 12.2 Hz), 3.79-3.87 (2H, m), 4.67 (1H, dd, J=3.6, 8.9 Hz),7.22-7.36 (7H, m), 7.44-7.47 (2H, m)

MS: [M+H]⁺=306

Melting point: 108.8° C.

Step 4-3: 4-Benzyl-6-(4-bromo-phenyl)-morpholin-3-one (Intermediate 32)

After addition of chloroacetyl chloride (8.49 g, 75.2 mmol) in toluene(30 ml) to a ice-cooled solution of2-benzylamino-1-(4-bromo-phenyl)-ethanol (intermediate 31, 21.85 g, 71.4mmol) in toluene (300 ml), a solution of triethylamine (10.25 g, 101mmol) in toluene (20 ml) was added to the mixture and stirred for onehour. Sodium methoxide (28% solution in methanol, 45.73 g, 237 mmol) inmethanol (30 ml) was then added to the solution and stirred for 2 hours.Reaction was quenched by adding dilute hydrochloric acid to adjust thepH around 7.0, and partitioned between water and ethyl acetate. Theorganic layer was washed with dilute hydrochloric acid, water, saturatedaqueous sodium bicarbonate, and brine and dried over sodium sulfate.Solvents were removed under reduced pressure, and the residue waspurified by silica gel column chromatography (eluent; hexane/ethylacetate=1/1) to afford 4-benzyl-6-(4-bromo-phenyl)-morpholin-3-one(intermediate 32, 21.26 g, 86%) as a colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 3.26 (1H, dd, J=3.4, 12.3 Hz), 3.35 (1H, dd,J=10.4, 12.3 Hz), 4.47 (1H, d, J=16.8 Hz), 4.51 (1H, d, J=16.6 Hz), 4.56(1H, d, J=14.6 Hz), 4.72 (1H, d, J=14.8 Hz), 7.19 (2H, d, J=8.4 Hz),7.27-7.38 (5H, m), 7.47 (2H, d, J=8.5 Hz)

MS: [M+H]⁺=346

Step 4-4: 4-Benzyl-2-(4-bromo-phenyl)-morpholine (Intermediate 33)

To a solution of 4-benzyl-6-(4-bromo-phenyl)-morpholin-3-one(intermediate 32, 18.70 g, 54 mmol) in tetrahydrofuran (100 ml) wasadded a solution of borane-tetrahydrofuran complex in tetrahydrofuran(0.9 M, 170 ml, 153 mmol) dropwise at 0° C. under nitrogen atmosphere.The resulting mixture was warmed to room temperature and stirred for 3hours. After cooling to 0° C., the reaction was quenched by the slowaddition of methanol (30 ml). The clear mixture was evaporated underreduced pressure and the residual oil was diluted with 1N aqueous sodiumhydroxide (300 ml). The resulting aqueous mixture was stirred at 100° C.for 3 hours and cooled to room temperature. The afforded organicmaterials were extracted with ethyl acetate and the combined extractswere dried over anhydrous sodium sulfate. After concentration, theresidue was purified by silica gel column chromatography (eluent;hexane/ethyl acetate=3/1) to yield4-benzyl-2-(4-bromo-phenyl)-morpholine (intermediate 33, 17.30 g, 52mmol, 96%) as colorless oil.

¹H NMR (400 MHz, CDCl₃) δ: 2.26 (1H, dt, J=3.4, 11.5 Hz), 2.74 (1H, dd,J=1.6, 11.5 Hz), 2.85-2.89 (1H, m), 3.82 (1H, dt, J=2.5, 11.4 Hz),3.98-4.02 (1H, m), 4.53 (1H, d, J=2.2, 10.2 Hz), 7.21 (2H, d, J=8.3 Hz),7.45 (2H, d, J=8.2 Hz)

MS: [M+H]⁺=332

Step 4-5: 2-(4-Bromo-phenyl)-morpholine-4-carboxylic acid tert-butylester (Intermediate 34)

To a solution of 4-benzyl-2-(4-bromo-phenyl)-morpholine (intermediate33, 10.0 g, 30 mmol) in dichloroethane (90 ml) was added chloroethylchloroformate (4.0 ml, 36 mmol) at room temperature and the resultingsolution was refluxed for one hour. After cooling to room temperature,the mixture was concentrated under reduced pressure. The residue wasdiluted with methanol (100 ml) and the resulting solution was refluxedfor one hour. Methanol was evaporated and ethyl acetate was added to theresidual solid. After triturating, white solid was collected byfiltration and dried under reduced pressure. The obtained solid wassuspended with tetrahydrofuran (60 ml) and to the resulting mixture wasadded di-tert-butyl dicarbonate (6.50 g, 30 mmol) and 1N aqueous sodiumhydroxide (60 ml, 60 mmol) at room temperature. After 2 hours stirring,extractive workup with ethyl acetate was performed and the combinedorganic phase was dried over anhydrous sodium sulfate followed byconcentration. The resulting solid was washed with hexane to afford2-(4-bromo-phenyl)-morpholine-4-carboxylic acid tert-butyl ester(intermediate 34, 9.08 g, 26.5 mmol, 88%) as a white solid, which wasused for next reaction without further purification

¹H NMR (400 MHz, CDCl₃) δ: 1.48 (9H, s), 2.77 (2H, br), 3.03 (1H, br),3.67 (1H, dt, J=2.4, 11.7 Hz), 3.94 (2H, br), 4.01 (1H, d, J=10.8 Hz),4.37 (1H, d, J=10.2 Hz), 7.24-7.26 (2H, m), 7.48-7.50 (2H, m)

MS: [M+H]⁺⁼²⁴² (-tert-butoxycarbonyl)

Melting point: 97.5° C.

Step 4-6:2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-morpholine-4-carboxylicacid tert-butyl ester (Intermediate 35)

A mixture of 2-(4-bromo-phenyl)-morpholine-4-carboxylic acid tert-butylester (intermediate 34, 6 g, 17.5 mmol), bis(pinacolato)diboron (5.1 g,20 mmol), potassium acetate (3.5 g, 36 mmol) and[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.2 g, 1.5mmol) in N,N-dimethylformamide (40 ml) was heated to 80° C. undernitrogen atmosphere. After stirring for 3 hours, the reaction mixturewas cooled to room temperature and poured into water. Extractive workupwas performed with ethyl acetate and the organic phase was washed withbrine. The collected organic layer was dried over sodium sulfate andconcentrated. The resulting material was purified by flash columnchromatography on silica gel (hexane/ethyl acetate=5/1 as an eluent).2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-morpholine-4-carboxylicacid tert-butyl ester (intermediate 35, 5.6 g, 14.5 mmol, 83% yield) wasobtained as a white solid.

¹H NMR (400 MHz, CDCl₃) δ: 1.34 (12H, s), 1.48 (9H, s), 2.80 (1H, br),3.05 (1H, br), 3.68 (1H, dt, J=2.3, 11.7 Hz), 3.94 (2H, br), 4.03 (1H,d, J=10.4 Hz), 4.43 (1H, d, J=9.8 Hz), 7.38 (2H, d, J=7.9 Hz), 7.81 (2H,d, J=7.9 Hz)

MS: [M+H]⁺=290 (-tert-butoxycarbonyl)

Melting point: 129.4° C.

Step 4-7: 2-(4-Furan-3-yl-phenyl)-morpholine-4-carboxylic acidtert-butyl ester (Intermediate 36)

A mixture of2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-morpholine-4-carboxylicacid tert-butyl ester (1.0 g, 2.6 mmol), 3-bromofuran (0.27 ml, 3.0mmol), tetrakis(triphenylphosphine)palladium(0) (0.35 g, 0.3 mmol) and2N aqueous potassium carbonate solution (4.5 ml) inN,N-dimethylformamide (5 ml) was heated to 80° C. under nitrogenatmosphere and stirred for 3 hours. The reaction mixture was poured intowater and extracted with ethyl acetate. The organic phase was washedwith brine and dried over sodium sulfate. After concentration, theresidue was purified to afford2-(4-furan-3-yl-phenyl)-morpholine-4-carboxylic acid tert-butyl ester(intermediate 36, 0.73 g, 2.2 mmol, 85% yield) as a white solid bysilica gel column chromatography (eluent; hexane/ethyl acetate=3/1).

¹H NMR (400 MHz, CDCl₃) δ: 1.49 (9H, s), 2.85 (1H, br), 3.06 (1H, br),3.69 (1H, dt, J=2.6, 11.8 Hz), 3.96 (2H, br), 4.03 (1H, d, J=10.1 Hz),4.43 (1H, d, J=9.2 Hz), 6.70 (1H, d, J=1.3 Hz), 7.38 (2H, d, J=8.0 Hz),7.47-7.49 (3H, m), 7.73 (1H, s)

MS: [M+H]⁺=230 (-tert-butoxycarbonyl)

Melting point: 114.0° C.

Step 4-8:2-[2-(4-Furan-3-yl-phenyl)-morpholin-4-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one(Compound 3 in Table 1)

2-(4-Furan-3-yl-phenyl)-morpholine-4-carboxylic acid tert-butyl ester(intermediate 36, 0.73 g, 2.2 mmol) was dissolved in 4N hydrogenchloride in ethyl acetate solution at room temperature and the mixturewas stirred for 2 hours. After concentration of the reaction mixture,the resulting solid materials were collected. The obtained solid wassuspended with tetrahydrofuran (10 ml). To the mixture was added2-chloro-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one (intermediate 1,0.33 g, 1.5 mmol) and triethylamine (0.62 ml, 4.5 mmol) at roomtemperature. After stirring for 6 hours, the resulting mixture waspoured into water and extracted with chloroform. The organic solutionwas dried over sodium sulfate and concentrated. The residue was purifiedby flash column chromatography on silica gel (chloroform/methanol=95/5as an eluent) to yield2-[2-(4-furan-3-yl-phenyl)-morpholin-4-yl]-1-methyl-1H-[4,4′]bipyrimidinyl-6-one(compound 3 in Table 1, 0.55 g, 1.3 mmol, 87%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ: 3.04 (1H, dd, J=10.8, 12.8 Hz), 3.20 (1H,dt, J=2.8, 12.4 Hz), 3.49 (3H, s), 3.71 (1H, d, J=13.4 Hz), 3.76 (1H, d,J=12.9 Hz), 3.92 (1H, dt, J=1.8, 11.7 Hz), 4.10 (1H, dd, J=1.8, 11.6Hz), 4.76 (1H, dd, J=1.9, 10.6 Hz), 6.98 (1H, s), 7.02 (1H, s), 7.47(1H, d, 8.2 Hz), 7.64 (1H, d, J=8.3 Hz), 7.75 (1H, d, J=1.6 Hz),8.21-8.22 (2H, m), 8.99 (1H, d, J=5.1 Hz), 9.30 (1H, s)

MS: [M+H]⁺=416

Melting point: 219.4° C. (decomp.)

Example 5 Preparation of the Compound 4 in Table 11-Methyl-2-{2-[4-(1-methyl-1H-imidazol-2-yl)-phenyl]-morpholin-4-yl}-1H-[4,4′]bipyrimidinyl-6-one

Step 5-1:2-[4-(1-Methyl-1H-imidazol-2-yl)-phenyl]-morpholine-4-carboxylic acidtert-butyl ester (Intermediate 37)

A mixture of2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-morpholine-4-carboxylicacid tert-butyl ester (intermediate 35, 1.0 g, 2.6 mmol),2-bromo-1-methyl imidazole (0.29 mL, 3.0 mmol),tetrakis(triphenylphosphine) palladium(0) (0.35 g, 0.3 mmol) and 2Naqueous potassium carbonate (4.5 ml) in N,N-dimethylformamide (5 ml) washeated to 80° C. under nitrogen atmosphere and stirred for 3 hours. Thereaction mixture was poured into water and extracted with ethyl acetate.The organic phase was washed with brine and dried over sodium sulfate.After concentration, the residue was purified by silica gel columnchromatography (eluent; ethyl acetate) to afford2-[4-(1-methyl-1H-imidazol-2-yl)-phenyl]-morpholine-4-carboxylic acidtert-butyl ester (intermediate 37, 0.40 g, 1.2 mmol, 45%) as colorlessoil.

¹H NMR (400 MHz, CDCl₃) δ: 1.49 (9H, s), 2.85 (1H, br), 3.07 (1H, br),3.66-3.76 (1H, m), 3.75 (3H, s), 3.95 (2H, br), 4.05 (1H, d, J=9.8 Hz),4.47 (1H, d, J=9.1 Hz), 6.97 (1H, s), 7.12 (11-1, d, J=1.0 Hz), 7.47(2H, d, J=8.1 Hz), 7.64 (2H, d, 8.3 Hz)

MS: [M+H]⁺=344

Step 5-2:1-Methyl-2-{2-[4-(1-methyl-1H-imidazol-2-yl)-phenyl]-morpholin-4-yl}-1H-[4,4′]-bipyrimidinyl-6-one(Compound 4 in Table 1)

2-[4-(1-Methyl-1H-imidazol-2-yl)-phenyl]-morpholine-4-carboxylic acidtert-butyl ester (intermediate 37, 0.40 g, 1.2 mmol) was dissolved in 4Nhydrogen chloride in ethyl acetate (5 ml) at room temperature and themixture was stirred for 2 hours. After concentration of the reactionmixture, the resulting solid materials were collected. The obtainedsolid was suspended with tetrahydrofuran (10 ml). To the mixture wasadded 2-chloro-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one(intermediate 1, 0.18 g, 0.8 mmol) and triethylamine (0.42 ml, 3 mmol)at room temperature. After stirring for 6 hours, the resulting mixturewas poured into water and extracted with chloroform. The organicsolution was dried over sodium sulfate and concentrated. The residue waspurified by silica gel column chromatography (eluent;chloroform/methanol=95/5) to yield1-methyl-2-{2-[4-(1-methyl-1H-imidazol-2-yl)-phenyl]-morpholin-4-yl}-1H-[4,4′]bipyrimidinyl-6-one(compound 4 in Table 1, 0.12 g, 0.3 mmol, 35%) as a white solid.

¹1H NMR (400 MHz, DMSO-d₆) δ: 3.07 (1H, dd, J=10.8, 12.8 Hz), 3.18-3.26(1H, m), 3.50 (3H, s), 3.73 (1H, d, J=13.1 Hz), 3.76 (3H, s), 3.82 (1H,d, J=13.0 Hz), 3.94 (1H, dt, J=2.1, 11.7 Hz), 4.10 (1H, d, J=13.1 Hz),4.82 (1H, dd, J=1.9, 10.3 Hz), 6.98 (1H, s), 7.02 (1H, s), 7.26 (1H, s),7.57 (2H, d, J=8.3 Hz), 7.71 (2H, d, J=8.4 Hz), 8.23 (1H, dd, J=1.2, 5.4Hz), 9.00 (1H, d, J=5.0 Hz), 9.30 (1H, d, J=1.1 Hz)

MS: [M+H]⁺=430

Melting point: 179.8° C. (decomp.)

Example 6 Preparation of the Compound 5 in Table 11-Methyl-2-[2-(4-pyrazol-1-yl-phenyl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one

Step 6-1: 2-(4-Pyrazol-1-yl-phenyl)-morpholine-4-carboxylic acidtert-butyl ester (Intermediate 38)

A mixture of 2-(4-bromo-phenyl)-morpholine-4-carboxylic acid tert-butylester (intermediate 34, 3.0 g, 8.8 mmol), copper (I) iodode (0.05 g, 0.3mmol), sodium iodide (1.8 g, 12 mmol) andtrans-N,N′-dimethylcyclohexane-1,2-diamine (0.1 ml, 0.6 mmol) in toluene(10 ml) was refluxed under nitrogen atmosphere for 3 hours. After themixture was cooled to room temperature, pyrazole (0.68 g, 10 mmol) andpotassium phosphate (6.4 g, 30 mmol) was added to the mixture. Theresulting mixture was refluxed for 3 hours and then cooled to roomtemperature. After removal of solid materials by filtration, thefiltrate was poured into water and extracted with ethyl acetate. Theorganic layer was dried over sodium sulfate and concentrated. Theresidue was purified by flash column chromatography on silica gel togive 2-(4-pyrazol-1-yl-phenyl)-morpholine-4-carboxylic acid tert-butylester (intermediate 38, 1.7 g, 5.3 mmol, 60%) as a white solid.

¹H NMR (400 MHz, CDCl₃) δ: 1.49 (9H, s), 2.84 (1H, br), 3.06 (1H, br),3.70 (1H, dt, J=2.4, 11.7 Hz), 4.04 (1H, d, J=10.1 Hz), 4.46 (1H, d,J=8.8 Hz), 6.47 (1H, t, J=2.0 Hz), 7.47 (2H, d, J=8.6 Hz), 7.70 (2H, d,J=8.5 Hz), 7.72 (1H, d, J=1.3 Hz), 7.93 (1H, d, J=2.4 Hz)

MS: [M+H]⁺=230 (-tert-butoxycarbonyl)

Melting point: 87.3° C.

Step 6-2:1-Methyl-2-[2-(4-pyrazol-1-yl-phenyl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one(Compound 5 in Table 1)

2-(4-Pyrazol-1-yl-phenyl)-morpholine-4-carboxylic acid tert-butyl ester(intermediate 38, 1.74 g, 5.3 mmol) was dissolved in 4N hydrogenchloride in ethyl acetate (10 ml) at room temperature and the mixturewas stirred for 2 hours. After concentration of the reaction mixture,the resulting solid materials were collected. The part of obtained solid(500 mg) was suspended with tetrahydrofuran (20 ml). To the mixture wasadded 2-chloro-3-methyl-6-(pyrimidin-4-yl)-3H-pyrimidin-4-one(intermediate 1, 0.33 g, 1.5 mmol) and triethylamine (0.62 ml, 4.5 mmol)at room temperature. After stirring for 6 hours, the resulting mixturewas poured into water and extracted with chloroform. The organicsolution was dried over sodium sulfate and concentrated. The residue waspurified by silica gel column chromatography (eluent;chloroform/methanol=95/5) to yield1-methyl-2-[2-(4-pyrazol-1-yl-phenyl)-morpholin-4-yl]-1H-[4,4′]bipyrimidinyl-6-one(compound 5 in Table 1, 0.44 g, 1.0 mmol, 70%) as a white solid.

¹H NMR (400 MHz, DMSO-d₆) δ: 3.05 (1H, dd, J=10.7, 12.8 Hz), 3.21 (1H,dt, J=2.5, 12.5 Hz), 3.49 (3H, s), 3.72 (1H, d, J=13.0 Hz), 3.79 (1H, d,J=13.0 Hz), 3.94 (1H, dt, J=1.8, 11.6 Hz), 4.10 (1H, dd, J=1.9, 11.7Hz), 4.80 (1H, dd, J=1.8, 10.4 Hz), 6.56 (1H, t, J=2.0 Hz), 7.02 (1H,s), 7.59 (2H, d, J=8.6 Hz), 7.76 (1H, d, J=1.4 Hz), 7.87 (2H, d, 8.6Hz), 8.22 (1H, dd, J=1.1, 5.3 Hz), 8.52 (1H, d, J=2.5 Hz), 9.00 (1H, d,J=5.2 Hz), 9.30 (11-1, d, J=1.2 Hz)

MS: [M+H]⁺=416

Melting point: 183.5° C.

Biological Assays

Experiment 7 Inhibitory Activity on Tau Phosphorylation In vivo

Test compound was administrated to male CD-1 mice of 5-6 weeks weighing25-35 g (Charles River Japan, inc.) at 10 mg/kg p.o. (0.5% polyethylenglycol sorbitan monolaurate 80 (Tween80)/water suspension) and after 1h, mice were decapitated and cortex was promptly removed, followed bybeing frozen in liquid N₂. Cortex was directly homogenized with 2.3%sodium dodecyl sulfate (SDS) homogenization buffer (62.5 mM2-amino-2-(hydroxymethyl)-1,3-propanediol hydrochloride (Tris-HCl), 2.3%SDS, 1 mM each of ethylendiaminetetraacetic acid (EDTA), ethyleneglycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) anddithiothreitol (DTT), protease inhibitor cocktail (sigma P2714)containing 0.2 μM 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), 13μM bestatin, 1.4 μM E-64, 0.1 mM leupeptin, 30 nM aprotinin, pH 6.8) andcentrifuged at 15000×g for 15 min at 4° C. Protein concentrations weredetermined using DC protein assay kit (BIO-RAM. Supernatants werediluted with sample buffer (62.5 mM Tris-HCl, 25% glycerol, 2% SDS,0.01% Bromophenol Blue, pH6.8) to adjust the protein concentrationsaround 0.5-2 mg/mg and then boiled for 5 min. Samples (10 it g) wereseparated on 10% sodium dodecyl sulfate-polyacrylamide electrophoresis(SDS-PAGE) mini slab gels and transferred onto polyvinylidene difluoride(PVDF) membranes. Membranes were incubated with phosphate bufferedsaline (PBS) containing 5% non-fat milk for 1 h at room temperature andthen probed with pS396 anti-body (BIOSOURCE) over night at 4° C.Anti-rabbit IgG horseradish peroxidase (HRP) conjugated antibody(Promega) was used as secondary anti-body. Membranes were visualized byEnhanced ChemiLuminescence (ECL) kit (Amersham Bioscience) and detectedby LAS1000 (Fuji Photo Film).

TABLE 1 in vivo¹⁾ COMPOUNDS 10 mg/kg Compound of the present invention58.14** 1 92.12 2 79.21 3 71.44 4 71.21 5 53.35** ¹⁾% phosphorylationagainst vehicle. **data means statistically significant

Experiment 8 Inhibitory Activity on CYP2D6

The purpose of this pharmacokinetic study was to investigate theinhibitory effects of test compounds on the specific metabolic activityof human CYP isozymes using human recombinant CYPs in vitro. The testcompounds at concentrations of 0.4, 2, 10 and 50 μmol/L (If testcompounds show low solubility in DMSO, the concentration was set 0.2, 1,5 and 25 μmol/L) or positive control was added to the reaction mixturecontaining CYP2D6. The specific substrate and positive control isethylene glycol ester of luciferin-6′-methyl ether and quinidine,respectively. The substrate for the CYP isozyme was incubated with humanrecombinant CYPs in the presence or absence of the test compounds andthe metabolic activity of the CYP isozyme was determined. The reactionmixture was preincubated at 37° C. without NADPH generating system. Thereaction was started by the addition of NADPH generating system, andthen terminated by the addition of acetonitrile. The activities of thehuman CYP isozymes were measured by fluorescence signal (CYP2D6) ofreaction mixture. IC₅₀ value for each compound was calculated by settingthe data of reaction mixture without compound as 100% activity.

TABLE 2 COMPOUNDS CYP 2D6 inhibition (μM)¹⁾ Compound of the presentinvention >50.0 1 >50.0 2 >25.0 3 2.3 4 >50.0 5 1.9 ¹⁾IC₅₀ value

Experiment 9 Procognitive Effect

Procognitive properties of the glycogen-synthase inhibitor,3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one, have beencharacterized on episodic memory deficits in normal andscopolamine-treated mice. Episodic memory was evaluated in the objectrecognition (OR) test.

The object recognition task was performed in a dimly illuminated (30Lux), Plexiglas open-field box. The objects to be discriminated were ablack plastic sphere and a black plastic cap. Mice were submitted to a10-min acquisition trial (first trial) during which they wereindividually placed in the open field in the presence of object A(sphere or cap). The mouse behaviour was registered on a videotape usinga camera and the time the animal took to explore object A (when theanimal's snout was directed toward the object at a distance #1 cm) wererecorded. A 10-min retention trial (second trial) occurred 3 hr or 24 hrlater. During this trial, object A and another object B were placed inthe open field, and the times (tA and tB) the animal took to explore thetwo objects were recorded. A recognition index (RI) was defined as(tB/(tA+tB))×100. An absence of recognition is chance with a theoricalvalue of 50%.

The deficit of memory was induced either by a 24 h delay between theacquisition and the retention trials, or by the administration of themuscarinic receptor antagonist scopolamine before the acquisition trial.

In normal mice, the inter-trial-interval between acquisition andretention sessions was 24 h, and3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-onewas administered per os either twice, 1 h before each session, or onceimmediately after the acquisition session. In scopolamine-treated mice,the inter-trial-interval between acquisition and retention sessions was3 h, scopolamine (1 mg/kg) was administered intraperitoneally 30 minutesbefore the acquisition session, and3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-onewas administered per os 1 h before the acquisition session.

In normal mice, 3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin.-4-yl)pyrimidin-4(31-1)-one (1-3-10-30mg/kg p.o.) increased significantly memory performance from the dose of10 mg/kg, when administered orally 1 h before acquisition and retentionsessions, indicating that treated mice remember the object explored 24 hbefore. RI values were 50%, 50.3%, 52.6%, 60.4%, and 62.9%, at 0, 1, 3,10, 30 mg/kg, respectively.

To distinguish the effect on memory acquisition from that on memoryconsolidation,3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-onewas administered once (3.10-30 mg/kg po) immediately after theacquisition phase.3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneameliorated significantly object recognition at doses of 10 and 30mg/kg, suggesting that the compound consolidates episodic memory at aminimal effective dose of 10 mg/kg. RI values were 50.7%, 54.6%, 58.6%,and 60.0%, at 0, 3, 10, 30 mg/kg, respectively.

In order to evaluate procognitive activity of3-Methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneon episodic memory deficits, mice were treated with the cholinergicantagonist scopolamine (1 mg/kg s.c.) 30 minutes before the acquisitionphase. Scopolamine completely abolished episodic memory, treated micedid not remember the object explored 3 h before. A single oraladministration of3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one(10 mg/kg) 30 minutes before scopolamine treatment, i.e. 1 h before theacquisition phase, totally reversed the episodic memory deficits inducedby scopolamine, the lower dose of 3 mg/kg being ineffective. RI valueswere 63.5%, 61.7%, and 59.7% in normal mice, and 49.9%, 52.7%, and 60.4%in scopolamine-treated mice, at 0, 10, 30 mg/kg, respectively.

Altogether, our behavioral results demonstrate that the TPK1 inhibitor3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)⁻6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneincreases episodic memory and consolidates episodic memory trace innormal mice at a minimal effective dose of 10 mg/kg. In addition,3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)6-(pyrimidin-4-yl)pyrimidin-4(3H)-oneprevents episodic memory deficits in scopolamine-treated mice (MED 10mg/kg). These behavioural data strongly support a precognitive potentialfor the3-methyl-2-((2S)-2-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)morpholino)-6-(pyrimidin-4-yl)pyrimidin-4(3H)-one.

Formulation Example

(1) Tablets

The ingredients below were mixed by an ordinary method and compressed byusing a conventional apparatus.

Compound of the present invention  30 mg (prepared in PreparationExample) Crystalline cellulose  60 mg Corn starch 100 mg Lactose 200 mgMagnesium stearate  4 mg(2) Soft Capsules

The ingredients below were mixed by an ordinary method and filled insoft capsules.

Compound of the present invention 30 mg (prepared in PreparationExample) Olive oil 300 mg  Lecithin 20 mg

INDUSTRIAL APPLICABILITY

The compounds of the present invention have TPK1 inhibitory activity andare useful as an active ingredient of a medicament for preventive and/ortherapeutic treatment of diseases caused by abnormal advance of TPK1such as neurodegenerative diseases (e.g. Alzheimer disease) and theabove-mentioned diseases.

What is claimed is:
 1. A method of treating Alzheimer's diseasecomprising administering a compound represented by formula (I)

or a pharmaceutically acceptable salt thereof to a patient in need ofsuch treatment.
 2. A method of treating non-insulin dependent diabetescomprising administering a compound represented by formula (I)

or a pharmaceutically acceptable salt thereof to a patient in need ofsuch treatment.
 3. A method of treating a cognitive and memory deficitcharacteristic of Alzheimer's disease comprising administering acompound represented by formula (I)

or a pharmaceutically acceptable salt thereof to a patient in need ofsuch treatment.